Iowa Medicaid Drug Utilization Review (DUR) Commission

May 4, 2022

Location: **Teleconference** (Due to PHE Declaration for the COVID-19 Pandemic)
Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:
https://changehealthcare.webex.com/changehealthcare/j.php?MTID=m7da031de52cc21d5ceb5ae16abff70ec
Dial In: 1-844-245-7693
Meeting Number: 2531 984 1383
Meeting Password: MRxmBSAM826

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the Minutes
    b) February 2022 DUR Recommendation Letter to DHS
    c) Follow-Up from Previous Meeting(s)
3. IME Pharmacy Update
4. Prevalence Report Summaries
    a) Fee-for-Service
    b) Amerigroup
    c) Iowa Total Care
    d) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit.
    - Written - Must submit written comments and a completed conflict of interest disclosure.
    - Reference complete public comment policy here.
    - **All submissions must be received no later than 4:30 p.m. CT April 27, 2022.**
    - Send to info@iadur.org ***Indicate in email if providing written comment or verbal comment***.
6. Retrospective DUR
    a) Data Presentation(s)
        i. SABA Overutilization without Controller Medication
        ii. Duplicate Therapy with Stimulants for ADHD

b) Proposal(s)
    i. High Dose Opioid (> 90 MME) without Opioid Reversal Agent
    ii. Opioid plus Buprenorphine for OUD
c) Commission Recommendations for Retrospective DUR Agenda Topics

7. Prospective DUR
    a) Initial Days Supply Limit – Benzodiazepines – Initial Review
    b) Benzodiazepine Cumulative Quantity Limit – Initial Review
    c) Short-Acting Beta Agonist Quantity Limit – Initial Review
    d) Anticonvulsant Quantity Limits –Second Review
8. Break (10 minutes)
9. Prior Authorization
    a) Tasimelteon (Hetlioz) – Initial Review
    b) Janus Kinase Inhibitors – Initial Review
    c) Tralokinumab-Idrm (Adbry) – Initial Review
    d) Crisaborole (Eucrisa) – Initial Review
    e) Extended-Release Formulations – Initial Review
    f) Non-Preferred Drug – Initial Review
    g) Biologicals for Hidradenitis Suppurativa – Initial Review
    h) Sedative/Hypnotics, Non-Benzodiazepine – Initial Review
    i) Pilocarpine 1.25% (Vuity) – Initial Review
    j) PCSK9 Inhibitors – Second Review
    k) Finerenone (Kerendia) – Second Review
    l) Odevixibat (Bylvay) – Second Review
    m) Pegcetacoplan (Empaveli) – Second Review
10. Miscellaneous
    a) DUR Digest Vol. 34, No. 2 – Initial Review
    b) MedWatch

    FDA Approves Treatment for Wider Range of Patients with Heart Failure

    FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

    FDA approves drug for treatment of seizures associated with rare disease in patients two years of age and older

    FDA approves new drug to improve heart function in adults with rare heart condition
11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a conflict of interest disclosure. Completed forms must be provided to DUR staff at least one week prior to

the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

Next Meeting
August 3, 2022
Location TBD